{"product_id":"thermofisher-bcg-matrix","title":"Thermo Fisher Scientific Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThermo Fisher Scientific’s BCG Matrix preview highlights its high-growth Stars in life sciences solutions, solid Cash Cows from analytical instruments, and potential Question Marks in emerging diagnostics—offering a snapshot of where revenue and market share are concentrated. This brief view hints at strategic priorities like scaling high-margin platforms and reassessing lower-performing units. Purchase the full BCG Matrix for quadrant-specific data, actionable recommendations, and ready-to-use Word and Excel deliverables to guide investment and resource allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioproduction Workflow Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioproduction Workflow Solutions is a Star: as biologics and biosimilars grown, Thermo Fisher (TMO) leads single-use tech (~40% global share in 2024) and cell culture media, driving high-margin growth; FY2024 bioproduction revenue eyeing ~22% of company sales (~$8.5B of $39B). \u003c\/p\u003e\n\u003cp\u003eThese units need heavy capex to add global capacity—Thermo Fisher spent $1.2B in capex on bioproduction 2024—but scale gives strong cash flow as biopharma expands manufacturing worldwide. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and Gene Therapy Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs personalized medicine grows, Thermo Fisher Scientific’s cell and gene therapy contract development and manufacturing organization (CDMO) sits in the BCG Matrix high-growth Stars quadrant, backed by over $2.5 billion invested in specialized viral-vector and cell-therapy facilities through 2024 and \u0026gt;25 global sites handling GMP production.\u003c\/p\u003e\n\u003cp\u003eThese services require heavy reinvestment—capex and R\u0026amp;D—yet with the global cell and gene therapy CDMO market projected at $15+ billion by 2026 and expected CAGR ~30% (2025–30), Thermo Fisher can convert scale into strong future cash flow as approvals rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCryo-Electron Microscopy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThermo Fisher Scientific dominates high-end cryo-electron microscopy (cryo-EM) with ~60–70% market share in direct electron detectors and microscopes, fueling structural biology and drug discovery where adoption grew ~18% CAGR 2019–2024; platforms drove \u0026gt;$1.2B in life-science instrument revenue in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Next-Generation Sequencing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThermo Fisher’s Clinical Next-Generation Sequencing (NGS) is a Star: Ion Torrent platform and companion diagnostics drove roughly $1.2B in sequencing-related revenue in 2024, with oncology and infectious-disease tests growing ~18% YoY as precision medicine demand rises.\u003c\/p\u003e\n\u003cp\u003eHigh growth (~15–20% CAGR in diagnostics through 2028) forces heavy R\u0026amp;D and regulatory spend, keeping this unit in a high-investment phase to secure market share and reimbursement pathways.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIon Torrent strong share in oncology\/infectious markets\u003c\/li\u003e\n\u003cli\u003e$1.2B sequencing revenue in 2024\u003c\/li\u003e\n\u003cli\u003eDiagnostics growth ~18% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eProjected 15–20% CAGR to 2028\u003c\/li\u003e\n\u003cli\u003eHigh R\u0026amp;D and regulatory costs sustain Star status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics CDMO Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThermo Fisher Scientific’s biologics CDMO (contract development and manufacturing organization) is a BCG Matrix Star: revenue grew ~18% in 2024 to about $6.2B for pharma services, driven by one-stop clinical-to-commercial offerings as biotech outsourcing rose—global biologics CMO market hit ~$64B in 2024 and is projected ~8–10% CAGR through 2030.\u003c\/p\u003e\n\u003cp\u003eThe capital-heavy model captures more value per program as clients shift from in-house production; Thermo’s multi-site capacity expansions and ~70% fill\/finish utilization in 2024 expanded market share and margin resilience.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 pharma services revenue ~ $6.2B\u003c\/li\u003e\n\u003cli\u003eGlobal biologics CMO market ~$64B (2024)\u003c\/li\u003e\n\u003cli\u003eProjected CAGR 8–10% to 2030\u003c\/li\u003e\n\u003cli\u003e~70% fill\/finish utilization (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThermo Fisher: Bioproduction \u0026amp; CDMO Powerhouse—High Growth, Heavy Capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThermo Fisher Stars: bioproduction, biologics CDMO, cell\/gene CDMO, cryo-EM, and Clinical NGS—high growth, heavy capex\/R\u0026amp;D, strong market shares (single-use ~40% 2024; cryo-EM 60–70%), FY2024 bioproduction ~$8.5B (~22% sales), pharma services ~$6.2B (2024), \u0026gt;$2.5B invested in cell\/gene sites through 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 Rev\u003c\/th\u003e\n\u003cth\u003eMarket Share\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioproduction\u003c\/td\u003e\n\u003ctd\u003e$8.5B\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003ctd\u003eCapex $1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma services\u003c\/td\u003e\n\u003ctd\u003e$6.2B\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eUtilization ~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Thermo Fisher: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest guidance and trend impacts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix mapping Thermo Fisher business units for quick portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Chemicals and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaboratory chemicals and consumables form Thermo Fisher Scientific’s cash cow, delivering steady recurring revenue via the Fisher Scientific distribution network that served ~400,000 customers in 2024; the segment helped sustain the company’s 2024 gross margin of 39.1%. These products hold a high market share in mature markets, needing relatively low marketing spend while generating strong operating cash flow—Thermo Fisher reported $5.4 billion operating cash flow in FY2024. The predictability of consumables sales funds R\u0026amp;D investments—company R\u0026amp;D was $2.2 billion in 2024—supporting higher-growth divisions without diluting capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMass Spectrometry Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThermo Fisher Scientific is a market leader in mass spectrometry, with Orbitrap and related platforms driving ~35% share of the high-resolution MS market as of 2025 and leadership across proteomics and analytical chemistry.\u003c\/p\u003e\n\u003cp\u003eThe large installed base—estimated at \u0026gt;15,000 Orbitrap-family instruments worldwide—generates recurring revenue from high-margin service contracts and consumables, contributing to Thermo Fisher’s Life Sciences Solutions margins above 28% in 2024.\u003c\/p\u003e\n\u003cp\u003eAs mass spec is a mature, steady-growth market (~3–5% CAGR projected 2025–2030), Thermo Fisher’s strategy emphasizes operational efficiency and cash flow maximization over aggressive share gains, focusing on installed-base monetization and lifecycle services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChromatography Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLiquid and gas chromatography systems are a mature, low-growth segment generating steady revenue for Thermo Fisher Scientific; in 2024 the company reported Analytical Technologies sales of $8.5B, with chromatography a large share driving stable margins.\u003c\/p\u003e\n\u003cp\u003eThermo Fisher holds a top market share—roughly 25–30% in LC\/GC instruments—and uses integrated software and consumables to create high switching costs and recurring revenue from service and consumables.\u003c\/p\u003e\n\u003cp\u003eThese platforms produce consistent operating cash and margins (Analytical margin ~22% in 2024), serving as cash cows that fund higher-growth areas like genomics and life sciences instrumentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional PCR and qPCR Instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThermo Fisher’s traditional PCR and qPCR instruments remain a steady revenue source: global PCR market was ~7.8 billion USD in 2024 with expected 3–4% CAGR, and Thermo holds a top-3 share, supplying instruments and routine reagents to clinical and research labs.\u003c\/p\u003e\n\u003cp\u003eReagent gross margins often exceed 60%, making this a classic cash cow that needs modest R\u0026amp;D and sales spend to sustain recurring consumables revenue; pandemic peak volumes have normalized.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket ~7.8B USD (2024)\u003c\/li\u003e\n\u003cli\u003eThermo Fisher top-3 share\u003c\/li\u003e\n\u003cli\u003eReagent GM \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003e3–4% steady CAGR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFisher Scientific Distribution Channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFisher Scientific’s distribution arm aggregates over 400,000 SKUs and serves 400,000+ customers, letting academic and industrial buyers procure widely from one platform; in 2024 it supported Thermo Fisher Scientific’s $40.8B revenue, contributing robust cash flows.\u003c\/p\u003e\n\u003cp\u003eIts scale—global logistics across 50+ countries and estimated market share \u0026gt;20% in lab supplies—creates a moat few smaller distributors can match in the mature lab-supply market.\u003c\/p\u003e\n\u003cp\u003eBy leveraging high share and broad catalog, the division converts sales into steady free cash flow, funding R\u0026amp;D and acquisitions while keeping margins resilient in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e400,000+ SKUs aggregated\u003c\/li\u003e\n\u003cli\u003e400,000+ customers served\u003c\/li\u003e\n\u003cli\u003ePresence in 50+ countries\u003c\/li\u003e\n\u003cli\u003eContributed to $40.8B company revenue (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated lab-supply market share \u0026gt;20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThermo Fisher 2024: $40.8B Revenue, $5.4B Op Cash — Consumables \u0026amp; Orbitrap Power Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThermo Fisher’s cash cows—consumables, chromatography, mass spec, PCR reagents, and Fisher distribution—delivered steady revenue and strong cash flow in 2024: $40.8B company revenue, $5.4B operating cash flow, 39.1% gross margin, R\u0026amp;D $2.2B; Orbitrap \u0026gt;15,000 installed units (~35% HR-MS share), Analytical sales $8.5B, reagent GM \u0026gt;60%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$40.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp CF\u003c\/td\u003e\n\u003ctd\u003e$5.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e39.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$2.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eThermo Fisher Scientific BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Thermo Fisher Scientific BCG Matrix report you'll receive after purchase—no watermarks, no demo content, just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747868782969,"sku":"thermofisher-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/thermofisher-bcg-matrix.png?v=1772202436","url":"https:\/\/growthsharematrix.com\/products\/thermofisher-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}